Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.

about

Drugs in Clinical Development for Fungal Infections.Present and Future Therapy of Infections

P2860

Q40070714-2195F223-7BB1-4108-8A36-811AA553C105 Q57177336-D07D74D0-A637-4E23-AED8-93181FE5AED3

P2860

Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.

Item

http://www.wikidata.org/entity/Q38852907

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Activity of VT-1129 against Cr ...... es with high fluconazole MICs.

@en

type

Item

label

Activity of VT-1129 against Cr ...... es with high fluconazole MICs.

@en

prefLabel

Activity of VT-1129 against Cr ...... es with high fluconazole MICs.

@en

P1476

Activity of VT-1129 against Cr ...... es with high fluconazole MICs.

@en

P2093

David B Meya

http://www.w3.org/2001/XMLSchema#string

Edward P Garvey

http://www.w3.org/2001/XMLSchema#string

Kirsten Nielsen

http://www.w3.org/2001/XMLSchema#string

Kyle D Smith

http://www.w3.org/2001/XMLSchema#string

Priya Vedula

http://www.w3.org/2001/XMLSchema#string

Robert J Schotzinger

http://www.w3.org/2001/XMLSchema#string

William J Hoekstra

http://www.w3.org/2001/XMLSchema#string

P2860

Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseas

Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study

Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates.

The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.

Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.

P304

453-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/MMY/MYW089

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David R. Boulware

P577

2016-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27664991

http://www.w3.org/2001/XMLSchema#string

Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.

about

P2860

P2860

Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698